Cargando…

Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. HCC incidence rate is sixth and mortality is fourth worldwide. However, HCC pathogenesis and molecular mechanisms remain unclear. The incidence of HCC is associated with genetic, environmental, and metabolic fact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Qiang, Wu, Liwei, Ji, Jie, Feng, Jiao, Dai, Weiqi, Li, Jingjing, Wu, Jianye, Guo, Chuanyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605923/ https://www.ncbi.nlm.nih.gov/pubmed/33150145 http://dx.doi.org/10.2147/JHC.S277870

Ejemplares similares

Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma
por: Feng, Jiao, et al.
Publicado: (2020)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

Correction to: Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway
por: Yu, Qiang, et al.
Publicado: (2022)

PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma
por: Feng, Jiao, et al.
Publicado: (2019)

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis
por: Li, Yan, et al.
Publicado: (2023)

Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis
por: Feng, Jiao, et al.
Publicado: (2020)

Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2
por: Liu, Tong, et al.
Publicado: (2020)

Fenofibrate Ameliorates Hepatic Ischemia/Reperfusion Injury in Mice: Involvements of Apoptosis, Autophagy, and PPAR-α Activation
por: Zhang, Jie, et al.
Publicado: (2021)

Quercetin shows anti‐tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway
por: Wu, Liwei, et al.
Publicado: (2019)

The Gut Microbiome and Ferroptosis in MAFLD
por: Ji, Jie, et al.
Publicado: (2023)

Cellular based immunotherapy for primary liver cancer
por: Zheng, Yuanyuan, et al.
Publicado: (2021)

Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma
por: Hsu, Hui-Tzu, et al.
Publicado: (2014)

Methyl jasmonate leads to necrosis and apoptosis in hepatocellular carcinoma cells via inhibition of glycolysis and represses tumor growth in mice
por: Li, Jingjing, et al.
Publicado: (2017)

Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death
por: Li, Sainan, et al.
Publicado: (2017)

Apigenin Alleviates Liver Fibrosis by Inhibiting Hepatic Stellate Cell Activation and Autophagy via TGF-β1/Smad3 and p38/PPARα Pathways
por: Ji, Jie, et al.
Publicado: (2021)

TGF‐β/Smad and JAK/STAT pathways are involved in the anti‐fibrotic effects of propylene glycol alginate sodium sulphate on hepatic fibrosis
por: Xu, Shizan, et al.
Publicado: (2020)

Prognostic and immunological significance of peroxisome proliferator-activated receptor gamma in hepatocellular carcinoma based on multiple databases
por: Wang, Chaoban, et al.
Publicado: (2022)

Promotion of colorectal cancer cell death by ezetimibe via mTOR signaling-dependent mitochondrial dysfunction
por: Zheng, Yuanyuan, et al.
Publicado: (2023)

Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)

Peroxisome proliferator-activated receptor γ ligand-induced growth inhibition of human hepatocellular carcinoma
por: Rumi, M A K, et al.
Publicado: (2001)

Decreased expression of peroxisome proliferator-activated receptor alpha indicates unfavorable outcomes in hepatocellular carcinoma
por: Xiao, Yong-bo, et al.
Publicado: (2018)

Procyanidin B2 inhibits the activation of hepatic stellate cells and angiogenesis via the Hedgehog pathway during liver fibrosis
por: Feng, Jiao, et al.
Publicado: (2019)

Alleviation of Hepatic Ischemia Reperfusion Injury by Oleanolic Acid Pretreating via Reducing HMGB1 Release and Inhibiting Apoptosis and Autophagy
por: Wang, Wenwen, et al.
Publicado: (2019)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

The long noncoding RNA TUG1 acts as a competing endogenous RNA to regulate the Hedgehog pathway by targeting miR-132 in hepatocellular carcinoma
por: Li, Jingjing, et al.
Publicado: (2017)

In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity
por: Li, Sainan, et al.
Publicado: (2016)

Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
por: Katoch, Swati, et al.
Publicado: (2022)

Long-Term Tetrabromobisphenol A Exposure Induces Gut Microbiota Imbalance and Metabolic Disorders via the Peroxisome Proliferator-Activated Receptor Signaling Pathway in the Regenerated Gut of Apostichopus japonicus
por: Song, Xiaojun, et al.
Publicado: (2023)

Peroxisome Proliferator-Activated Receptor γ Expression Is Inversely Associated with Macroscopic Vascular Invasion in Human Hepatocellular Carcinoma
por: Hsu, Hui-Tzu, et al.
Publicado: (2016)

Hepatocellular proliferation in response to agonists of peroxisome proliferator-activated receptor alpha: a role for kupffer cells?
por: Alsarra, Ibrahim A, et al.
Publicado: (2006)

Chondrosarcoma and Peroxisome Proliferator-Activated Receptor
por: Nishida, K., et al.
Publicado: (2008)

15-Deoxy-∆-(12,14)-Prostaglandin J2 (15d-PGJ2), an Endogenous Ligand of PPAR-γ: Function and Mechanism
por: Li, Jingjing, et al.
Publicado: (2019)

Astaxanthin in Liver Health and Disease: A Potential Therapeutic Agent
por: Li, Jingjing, et al.
Publicado: (2020)

Luteolin Pretreatment Attenuates Hepatic Ischemia-Reperfusion Injury in Mice by Inhibiting Inflammation, Autophagy, and Apoptosis via the ERK/PPARα Pathway
por: Jiang, Yuhui, et al.
Publicado: (2022)

Cordycepin Protects against Hepatic Ischemia/Reperfusion Injury via Inhibiting MAPK/NF-κB Pathway
por: Ding, Jiameng, et al.
Publicado: (2022)

Research progress of gut microbiota in hepatocellular carcinoma
por: Li, Keliu, et al.
Publicado: (2022)

Peroxisome proliferator‐activated receptor gamma (PPARγ) regulates lactase expression and activity in the gut
por: Fumery, Mathurin, et al.
Publicado: (2017)

Ligands of the peroxisome proliferator-activated receptor γ inhibit hepatoce llular carcinoma cell proliferation
por: Jin, Zhe, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_er9d2lu5b2b7phhes2d7menkoh